Skip to main content
. 2022 May 9;54(1):1287–1296. doi: 10.1080/07853890.2022.2059559

Table 4.

Key highlights of bempedoic acid.

  1. February 2020, USA FDA approved bempedoic acid as a single agent and bempedoic acid with ezetimibe combination for adults with heterozygous familial hypercholesterolaemia or established atherosclerotic cardiovascular disease.

  2. Phase III trials showed its efficacy in lowering LDL-C

  3. It reduces hs-CRP level besides reduction of LDL-C

  4. Weight neutral, does not affect blood pressure or glucose metabolism

  5. Need future trials to look for this simultaneous LDL-C and hs-CRP lowering effects translating into CV mortality benefits